Saint-Genis-Pouilly

Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Company, Pharma, Society, Mythic Imagination Institute, Date, Congress, Lymphoma, Inhibitor, IND, Saint-Genis-Pouilly, Mantle cell lymphoma, CHEK1, Multiple myeloma, ATR, Lymphatic system, Date and time notation in the United Kingdom, Hematology, Time, Cancer, CTA, Pharmaceutical industry, Fine chemical, Idinvest Partners

Step Pharma and collaborators will present two posters on STP938, its potent and highly selective small molecule inhibitor of CTPS1, reporting its potential as a targeted therapeutic for the treatment of Mantle Cell Lymphoma and Multiple Myeloma.

Key Points: 
  • Step Pharma and collaborators will present two posters on STP938, its potent and highly selective small molecule inhibitor of CTPS1, reporting its potential as a targeted therapeutic for the treatment of Mantle Cell Lymphoma and Multiple Myeloma.
  • The Company is the world leader in CTPS1 inhibition, a new approach with the potential to yield highly selective, safe and effective cancer treatments for both blood cancers and solid tumours.
  • STP938 has the potential to be the backbone of a multitude of cancer therapies as well as a potent monotherapy for hard-to-treat blood cancers.
  • Step Pharma was founded in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour.

Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas

Retrieved on: 
Monday, October 24, 2022
Pharma, Saint-Genis-Pouilly, Mythic Imagination Institute, IND, Lymphoma, Lymphatic system, Cancer, Company, Adult, CTA, Safety, Pharmaceutical industry, Fine chemical, Idinvest Partners

The primary objective in Phase I is to assess the safety and tolerability of STP938.

Key Points: 
  • The primary objective in Phase I is to assess the safety and tolerability of STP938.
  • Brian Schwartz, Chief Medical Officer of Step Pharma, commented: We are developing STP938, a highly selective, first-in-class treatment based on ground-breaking genetics.
  • The dosing of the first patient into our Phase 1/2 trial is an important step to identify an optimal dose to take forward into further clinical development for relapsed/ refractory T cell and B cell lymphomas.
  • By targeting CTPS1, Step Pharma has unlocked the ability to selectively target the de novo pyrimidine synthesis pathway in cancer cells.

Step Pharma Progresses into Oncology Clinical Trials with STP938, the World’s Most Advanced CTPS1 Inhibitor

Retrieved on: 
Thursday, July 28, 2022
Mature T-cell lymphoma, DNA, Patient, Saint-Genis-Pouilly, Health care, MHRA, Food, Mythic Imagination Institute, CTA, Adult, Safety, Lymphoma, Cancer, Drug discovery, Pharma, FDA, Company, Blood, Medicines and Healthcare products Regulatory Agency, Pharmacokinetics, Lymphatic system, Criticism of the Food and Drug Administration, IND, Fine chemical, Pharmaceutical industry, Medical imaging, Idinvest Partners

Step Pharma is pioneering a novel class of oral drugs that specifically inhibits nucleotide synthesis and the enzyme cytidine triphosphate synthase 1 (CTPS1) in particular, originally identified as an essential gene for lymphocyte proliferation.

Key Points: 
  • Step Pharma is pioneering a novel class of oral drugs that specifically inhibits nucleotide synthesis and the enzyme cytidine triphosphate synthase 1 (CTPS1) in particular, originally identified as an essential gene for lymphocyte proliferation.
  • By targeting CTPS1, Step Pharma has unlocked the ability to selectively target the de novo pyrimidine synthesis pathway in cancer cells.
  • Step Pharmas goal is to bring about a step change in how cancer is treated with targeted therapies that kill cancer cells and leave healthy cells unharmed.
  • Step Pharma was founded in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour.